Alteogen signs $365m Hybrozyme licensing deal with pharma company
Alteogen is set to receive an upfront payment and could earn additional amounts through development, regulatory, and sales milestone payments.
Drug Development
Schrödinger and BMS expand partnership to deploy AI for drug discovery
AsymBio to secure $184m to support growth in biologics manufacturing
Phylo and Chugai collaborate to deploy AI platform in drug discovery
FDA grants breakthrough therapy designation to Lilly’s olomorasib
Curium to acquire Lantheus in all-cash deal worth up to $8bn
IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib
Ratio Therapeutics secures $70m Series C funding for cancer radiotherapy
